If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech company focused on artificial intelligence (AI), went public in April 2021. This was before ChatGPT, before AI became the hottest topic on Wall Street, and before the technology caused some companies' profits to soar. One might think that Recursion would have benefited from the rapid expansion and adoption of AI technology, but that hasn't exactly been the case, to say the least.Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future.It can take about 10 years (plus or minus a few) for a brand-new clinical compound to go from the early stages of discovery to the market, and those are just the ones that make it that far. Many are abandoned at some point after they fail to prove safe or effective in clinical studies.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool